Sometimes shame is just bravado
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 15, 155163
72-week results in adults with obesity (BMI 30), without diabetes
What to Expect From GLP-1 Medications The effects of GLP-1s can be felt almost immediately in some people
KFFs analysis of newly released Medicare Part D spending data from CMS shows that total gross Medicare spending on the three newest versions of these diabetes medications that have also been recently approved for weight loss Ozempic, Rybelsus, and Mounjaro has skyrocketed in recent years, rising from $57 million in 2018 to $5.7 billion in 2022 (Figure 1)
If you would like to discuss your weight loss goals and options, please call our office to make an appointment.